The FDA has approved Botox (onabotulinumtoxin A, from Allergan) for the treatment of spasticity in the flexor muscles of the elbow, wrist, and fingers in adults. This approval was based on data from double-blind, placebo-controlled studies that evaluated Botox in post-stroke patients with increased elbow, wrist, and/or finger flexor tone. Results from these studies found that Botox produced a statistically significant reduction in elbow, wrist, and finger flexor tone compared to placebo.
Botox is already indicated for the treatment of abnormal head position and neck pain in cervical dystonia (CD) in adults, strabismus or blepharospasm in patients ≥12 years old, and for the treatment of symptoms of severe primary axillary hyperhidrosis when topical medicines are not adequate.
For more information call (800) 433-8871 or visit www.botox.com.